PerkinElmer, Cerep Partner on Drug Discovery Tools | GenomeWeb
NEW YORK (GenomeWeb News) – PerkinElmer today announced that it has signed a co-marketing agreement with Cerep to provide custom drug discovery tools and services to customers.
 
Under the agreement, PerkinElmer will exclusively market Cerep’s target screening and profiling services to its customers. The firms also will jointly promote PerkinElmer’s assay technologies and Cerep’s high-throughput screening and profiling services to the drug discovery market.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.